Health CarePharmaceuticals & Biotechnology
  • Price (USD)4.88
  • Today's Change0.045 / 0.93%
  • Shares traded21.88m
  • 1 Year change-72.21%
  • Beta1.3065
Data delayed at least 15 minutes, as of Oct 18 2019 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

  • Revenue in USD (TTM)2.95bn
  • Net income in USD-516.55m
  • Incorporated2013
  • Employees2.91k
  • Location
    Endo International PLCMinerva House, Simmonscourt RoadDUBLIN 000 00IrelandIRL
  • Phone+353 12682000
  • Websitehttp://www.endo.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Editas Medicine Inc25.04m-103.33m976.94m133.00--5.03--39.02-2.13-2.130.5183.920.0668--133.89188,248.10-27.59-42.45-31.68-47.40-----412.70-776.14----0.00--132.64--8.62--145.79--
Alector Inc28.17m-75.81m990.15m101.00--4.03--35.15-1.26-1.260.45093.570.0749----361,153.80-20.16---23.39-------269.12------0.00--641.02---60.86------
AnaptysBio Inc10.00m-78.99m1.00bn78.00--2.23--100.18-3.00-3.000.381116.580.0254--3.88128,205.10-20.10-13.42-21.39-14.43-----789.92-150.34----0.0106---50.00-1.83-105.04--95.73--
Fate Therapeutics Inc8.14m-76.05m1.02bn104.00--6.98--125.98-1.22-1.220.13071.950.0575----78,230.77-53.74-43.83-64.08-50.53-----934.70-1,268.49----0.1047--15.4437.31-55.05--56.67--
Arvinas Inc14.85m-173.10m1.04bn103.00--4.16--69.85-5.54-5.540.47443.700.1068--8.83178,896.50-43.91---50.92-------411.12------0.0175--89.00---738.05------
Silk Road Medical Inc-100.00bn-100.00bn1.05bn176.00--12.46----------2.74------------------------13.38--0.3463--142.37---94.40------
Viela Bio Inc20.00m-57.19m1.06bn80.00------53.06-1.56-1.560.54594.72------250,000.00-------------285.93------0.00--------------
Esperion Therapeutics Inc146.40m-76.79m1.06bn76.00--8.18--7.26-3.04-3.045.374.780.5634----1,926,329.00-29.55-49.40-35.68-54.15-----52.45------0.00-------20.85--36.93--
Gossamer Bio Inc0.00-165.31m1.09bn118.00--2.26-----2.54-2.540.007.300.00----0.00-58.84---62.60--------------0.0602-------2,070.57------
Innoviva Inc260.83m382.38m1.10bn6.003.214.842.614.213.373.372.302.240.5318--3.7843,471,330.0082.6622.1685.8423.49----155.4575.33--15.590.610529.2420.16124.94194.50------
ArQule, Inc.9.55m-33.47m1.10bn36.00--6.79--115.02-0.307-0.3070.08771.340.0804--4.12265,166.70-28.20-36.42-31.20-47.24-----350.57-197.42----0.0845----10.1246.98------
Endo International PLC2.95bn-516.55m1.10bn2.91k----7.440.3739-2.30-2.6313.13-2.610.28214.796.561,014,431.00-4.94-8.83-6.10-11.1444.9139.02-17.50-35.381.321.051.08---15.046.7624.65---4.45--
Dicerna Pharmaceuticals Inc11.88m-87.63m1.12bn78.00--7.00--94.35-1.37-1.370.18652.340.0527--15.00152,243.60-38.85-52.76-51.70-62.20-----737.94-4,155.42----0.00--499.61---10.66---2.76--
Enanta Pharmaceuticals Inc221.09m64.61m1.18bn113.0019.382.6217.375.323.083.0810.5222.770.5186--4.351,956,540.0015.1617.9315.8018.67----29.2237.70----0.00410.00100.9745.17327.76--37.52--
Audentes Therapeutics Inc0.00-166.04m1.22bn207.00--2.90-----3.95-3.950.009.250.00----0.00-39.34-39.84-41.51-42.91------------0.00-------82.23--155.80--
Data as of Oct 18 2019. Currency figures normalised to Endo International PLC's reporting currency: US Dollar USD

Institutional shareholders

55.21%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 201930.21m13.34%
The Vanguard Group, Inc.as of 30 Jun 201928.12m12.42%
Glenview Capital Management LLCas of 30 Jun 201913.80m6.10%
Renaissance Technologies LLCas of 30 Jun 201911.71m5.17%
Miller Value Partners LLCas of 30 Jun 20199.80m4.33%
Paulson & Co., Inc.as of 30 Jun 20198.63m3.81%
SSgA Funds Management, Inc.as of 30 Jun 20197.65m3.38%
OrbiMed Advisors LLCas of 30 Jun 20196.17m2.72%
Morgan Stanley & Co. LLCas of 30 Jun 20194.88m2.16%
Invesco Capital Management LLCas of 30 Jun 20194.03m1.78%
More ▼
Data from 30 Jun 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.